These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 17374735

  • 21. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.
    Bethke TD, Huennemeyer A, Lahu G, Lemmer B.
    Chronobiol Int; 2010 Oct; 27(9-10):1843-53. PubMed ID: 20969527
    [Abstract] [Full Text] [Related]

  • 22. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
    Scott G, Vinluan Reynolds C, Milosavljev S, Langholff W, Shenouda M, Rordorf C.
    Clin Pharmacokinet; 2004 Oct; 43(5):341-8. PubMed ID: 15080766
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antacid and formula effects on gastric acidity in infants with gastroesophageal reflux.
    Sutphen JL, Dillard VL, Pipan ME.
    Pediatrics; 1986 Jul; 78(1):55-7. PubMed ID: 3725503
    [Abstract] [Full Text] [Related]

  • 25. [Serum and urine electrolyte behavior under therapeutic dosage of a potent magnesium and aluminum hydroxide containing antacid].
    Grünzig G, Lücker PW, Schnitker J.
    Arzneimittelforschung; 1983 Jul; 33(2):258-62. PubMed ID: 6682667
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of antacid suspension on the pharmacokinetics of ibuprofen.
    Gontarz N, Small RE, Comstock TJ, Stalker DJ, Johnson SM, Willis HE.
    Clin Pharm; 1987 May; 6(5):413-6. PubMed ID: 3665393
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
    Eckermann G, Lahu G, Nassr N, Bethke TD.
    J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
    [Abstract] [Full Text] [Related]

  • 30. Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
    Shen Z, Lee CA, Valdez S, Yang X, Wilson DM, Flanagan T, Gillen M.
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):647-656. PubMed ID: 30748125
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
    Huang Z, Dias R, Jones T, Liu S, Styhler A, Claveau D, Otu F, Ng K, Laliberte F, Zhang L, Goetghebeur P, Abraham WM, Macdonald D, Dubé D, Gallant M, Lacombe P, Girard Y, Young RN, Turner MJ, Nicholson DW, Mancini JA.
    Biochem Pharmacol; 2007 Jun 15; 73(12):1971-81. PubMed ID: 17428447
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE.
    Eur J Pharmacol; 2007 Oct 01; 571(2-3):215-21. PubMed ID: 17610865
    [Abstract] [Full Text] [Related]

  • 35. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study].
    Eichhorn M.
    Fortschr Med; 1989 Aug 10; 107(23):502-6. PubMed ID: 2670719
    [Abstract] [Full Text] [Related]

  • 36. [Mineral metabolism and aluminum burden with hydrotalcit. A placebo-controlled randomized double-blind study].
    Dollinger HC.
    Fortschr Med; 1991 Jun 20; 109(18):385-8. PubMed ID: 1916557
    [Abstract] [Full Text] [Related]

  • 37. [Study on the interactions during storage of compounds of the antacid group. I. Interactions of the components in suspensions].
    Pawlaczyk J, Lutka A.
    Acta Pol Pharm; 1989 Jun 20; 46(1):74-80. PubMed ID: 2816464
    [Abstract] [Full Text] [Related]

  • 38. [Selective phosphodiesterase 4 inhibition. Controlling inflammation--also in patients with COPD].
    MMW Fortschr Med; 2004 Apr 29; 146(18):59. PubMed ID: 15366479
    [No Abstract] [Full Text] [Related]

  • 39. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
    McCluskie K, Klein U, Linnevers C, Ji YH, Yang A, Husfeld C, Thomas GR.
    J Pharmacol Exp Ther; 2006 Oct 29; 319(1):468-76. PubMed ID: 16861399
    [Abstract] [Full Text] [Related]

  • 40. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
    Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W.
    J Clin Pharmacol; 2002 Mar 29; 42(3):297-303. PubMed ID: 11865966
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.